OncoMatch/Clinical Trials/NCT05726292
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Is NCT05726292 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Relacorilant and Enzalutamide for prostate cancer.
Treatment: Relacorilant · Enzalutamide — Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage LOCALIZED, CLINICAL T3A OR HIGHER
Excluded: Stage DISTANT METASTATIC DISEASE
Grade: Grade Group 4Grade Group 5 (NCCN/ISUP)
Localized disease; High or very high-risk disease (NCCN) as defined by having one or more of the following: Clinical T3a or higher, Histologic Grade Group 4 or 5, PSA >20
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hormonal therapy for prostate cancer
Exception: prior 5-alpha-reductase inhibitors for benign prostate disease is allowed but must be discontinued prior to study initiation
Therapy with ANY hormonal therapy for prostate cancer (prior 5-alpha-reductase inhibitors for benign prostate disease is allowed but must be discontinued prior to study initiation)
Lab requirements
Blood counts
Platelet count ≥100,000 /L; Hemoglobin ≥10 g/dL; Absolute neutrophil count (ANC) ≥1500
Kidney function
glomerular filtration rate (GFR) ≥30 mL/min
Liver function
Total bilirubin <1.5 X ULN (Gilbert's syndrome exception: if direct bilirubin ≤1.5 X ULN, eligible); AST(SGOT)/ALT(SGPT) <2.5 X ULN; Albumin ≥3.0 g/dL
Patients must have normal hepatic function as defined below: Total bilirubin <1.5 X ULN...AST(SGOT)/ALT(SGPT) <2.5 X ULN...Albumin 3.0 g/dL; Patients must have normal bone marrow function as defined below: Platelet count (plt) 100,000 /L; Hemoglobin (Hgb) 10 g/dL; Absolute neutrophil count (ANC) 1500; Patients must have adequate renal function as defined below: glomerular filtration rate (GFR) 30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Comprehensive Cancer Center · Chicago, Illinois
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify